MYOMO, INC.

MYO
About the company

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.

Country: United StatesPrice: $1.23Market Cap: $49.3M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2836 (Top 91.6%)FAILFAILFAILFAILFAILFAILPASSFAILPASSFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio4.2x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-24.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-24.7%, ROC=-531.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share4.2x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-33.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=4.2x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low182% of trailing low ($0.68)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-30.57%; #4811/6340 (top 75.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.0558; #4975/6449 (top 77.1%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share4.15x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.9225; #1858/5247 (top 35.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-32.95%; #3699/4519 (top 81.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+78.26%; #441/6202 (top 7.1%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-16.3M
      ✗LynchPositive and growing
      Operating Cash Flow$-14.5M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-37.56%, ROA=-40.31%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-33.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/10 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-34.3%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/10 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-16.3M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-32.95%; #3699/4519 (top 81.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag MYO's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/11 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/11 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-97.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-35.2% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-548.1%
      ✗Lynch> 15%
      EBIT / Enterprise Value-24.7%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-24.7%, ROC=-531.5%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-40.31%
      ✗PiotroskiROA > 0
      ROA Change YoY-14.64% -> -40.31% (delta: -25.67%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-37.56%, ROA=-40.31%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY71.2% -> 65.7%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-32.2%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-548.1%
      ✗Dreman> 12%
      Margin of SafetyP/B=4.2x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-84.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-21.8%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-548.1%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-42.8% (2023) -> -35.2% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 68.5% -> 65.7%, operating margin -42.8% -> -35.2%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-30.57%; #4811/6340 (top 75.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+94.42%; #161/3702 (top 4.3%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-548.13%; #5086/5226 (top 97.3%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2966; #4596/5884 (top 78.1%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts13% pass✓ 2✗ 14▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2836✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1811/2370 (Top 76.4%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Growth25% pass✓ 5✗ 8▾

      6 of 8 flag MYO's growth — Graham, Lynch, Dreman +3 more

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -15.1% vs Rev: 9.3%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-4.13 (2016) -> $-0.37 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth25.7%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency4/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 68.5% -> 65.7%, operating margin -42.8% -> -35.2%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR40.1%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag MYO's efficiency — Graham, Buffett, Greenblatt +3 more

      Current Ratio1.92
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-584.6%
      ✗Buffett> 10%
      ROIC - WACC-594.6%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-531.5%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.22 -> 3.30
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.77x -> 1.06x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities1.92
      ✓Dreman> 1.5
      Return on Invested Capital-166.4%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=-19.8%; FY2025: ROIC=-50.3%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/2 years above 12% (latest -50.3%)
      ✗SleepROIC > 12% in a majority of years
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag MYO's debt & leverage — Graham, Buffett, Lynch +5 more

      LT Debt vs Net Current AssetsLT Debt $11.7M vs NCA $11.2M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.98, IC: -128.7x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.71
      ✗Lynch< 0.33
      Cash - Long-term Debt$-0.6M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 29.05%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.92
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.71
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.71
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-128.7x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.71
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.7105; #2863/4210 (top 68.0%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($49.3M)
    Revenue: $40.9M+25.7% YoY
    Net Income: $15.6M-151.9% YoY

    Financial Snapshot

    Operating Margin-35.2%
    Return on Equity-136.6%
    Debt / Equity0.98
    Current Ratio3.30
    EPS (Diluted)$-0.37
    Shares Retired−12.0% / −41.9% 2y

    Shareholder Return

    Fiscal 2025

    Issued 12.0% of shares last year, 41.9% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-09
    FY 2024
    Sources
    • 10-K · 2025-03-10
    FY 2023
    Sources
    • 10-K · 2024-03-08
    FY 2022
    Sources
    • 10-K · 2023-03-13
    FY 2021
    Sources
    • 10-K · 2023-03-13
    Market Cap$49.3Mcurrent------$32.3Mest.$207.3Mest.$90.4Mest.$3.7Mest.$49.5Mest.
    Revenue$45.5M↑9%$12.3M↑22%$11.7M↑21%$10.1M↑3%$40.9M↑26%$32.6M↑69%$19.2M↓98%$1.0B↑7117%$13.9M
    Operating Income-$9.9M↑17%-$1.7M↑51%-$2.3M↑51%-$3.2M↑10%-$14.4M↓132%-$6.2M↑25%-$8.2M↑23%-$10.7M↓4%-$10.3M
    Net Income-$15.1M↓25%-$4.2M↓16%-$4.0M↑13%-$3.0M↑13%-$15.6M↓152%-$6.2M↑24%-$8.1M↑24%-$10.7M↓3%-$10.4M
    EPS (Diluted)--$-0.10↓11%$-0.09↑18%$-0.07↑12%$-0.37↓131%$-0.16↑43%$-0.28↑82%$-1.52↑20%$-1.89
    Gross Margin70.1%↑5%71.3%↑12%72.1%↑15%68.2%↑2%65.7%↓8%71.2%↑4%68.5%↑6582%1.0%↓99%74.4%
    Operating Margin-21.8%↑24%-14.0%↑60%-19.3%↑59%-31.2%↑13%-35.2%↓85%-19.1%↑55%-42.8%↓3909%-1.1%↑99%-74.1%
    ROE-548.1%↓567%———-136.6%↓446%-25.0%↑72%-90.6%↑46%-168.6%↓150%-67.3%
    Total Debt$2.0M↓19%$2.0M↓19%$611.4K↓54%$10.9M$11.2M$0------
    Shareholders' Equity$2.8M↓81%$2.8M↓81%$5.8M↓67%$9.0M↓58%$11.4M↓54%$24.7M↑175%$9.0M↑41%$6.4M↓59%$15.4M
    Current Ratio1.92↓23%1.92↓23%2.31↓3%2.73↑3%3.30↑2%3.22↑29%2.49↓3%2.56↓43%4.46
    Debt / Equity0.71↑330%0.71↑330%0.10↑39%1.210.980.00———
    Operating Cash Flow-$6.6M↑34%-$1.3M↑29%-$1.9M↑78%-$2.2M↑18%-$14.5M↓341%-$3.3M↑47%-$6.2M↑40%-$10.2M↓7%-$9.5M
    Free Cash Flow---$1.4M↑53%-$2.0M↑80%-$2.5M↑25%-$16.3M↓250%-$4.7M↑26%-$6.3M↑39%-$10.3M↓5%-$9.9M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    MYO vs Peers — Financial Grading

    Revenue$40.9MBottom 25%
    Net Income$15.6MBottom 25%
    ROE-136.6%Bottom 25%
    D/E0.98Bottom 25%
    Op. Margin-35.2%Bottom 25%
    Curr. Ratio3.30Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11